

Supplementary Materials for
Consolidated Financial Results
for the 3rd Quarter of Fiscal Year 2010. 12



CHUGAI PHARMACEUTICAL CO., LTD.



A member of the Roche group

- Notes: 1. Portions of this report that refer to performance forecasts or any other future events are believed to be reasonable under information available at the time of the forecasts. Actual results may materially differ from these forecasts due to potential risks and uncertainties.
2. Amounts shown in Financial Highlights, Statements of Revenues, Balance Sheets, Cash Flows and Capital Expenditures of this report are rounded to the nearest 0.1 billion yen. Variance and % are calculated based on the amounts shown.
3. Exchange rates used for each period are as follows.

(Yen)

| Fx rates | FY2007 | FY2008 | FY2009 | | | | FY2010 | | | | Revised Forecast |
|----------|-------------|-------------|---------|---------|---------|---------|---------|---------|---------|---------|------------------|
| | 1-12 | 1-12 | 1-3 | 1-6 | 1-9 | 1-12 | 1-3 | 1-6 | 1-9 | 1-12 | FY2010 |
| | (Full-year) | (Full-year) | (YTD) | (YTD) | (YTD) | (YTD) | (YTD) | (YTD) | (YTD) | (YTD) | 10-12 |
| | average | average | average | average | average | average | average | average | average | average | forecast |
| CHF | 98.13 | 95.54 | 81.55 | 84.52 | 85.68 | 86.20 | 85.80 | 84.42 | 84.00 | — | 85.00 |
| EUR | 161.17 | 151.38 | 122.06 | 127.19 | 129.32 | 130.10 | 125.58 | 121.21 | 117.66 | — | 119.00 |
| USD | 117.80 | 103.44 | 93.51 | 95.46 | 94.87 | 93.60 | 90.69 | 91.41 | 89.56 | — | 89.00 |
| GBP | 235.66 | 189.85 | 134.34 | 142.14 | 145.77 | 145.99 | 141.62 | 139.45 | 137.32 | — | 140.00 |

Financial Highlights (YTD)

(Billions of Yen)

| | FY2007 | FY2008 | FY2009 | | | | FY2010 | | | | | | | | Revised Forecasts | | | |
|---------------------------------|--------|--------|--------|-------|-------|-------|--------|------------|-------|------------|-------|------------|------|------------|-------------------|------------|-----------|------------|
| | | | FY2009 | | | | FY2010 | | | | | | | | FY2010 | | | |
| | | | 1-3 | 1-6 | 1-9 | 1-12 | 1-3 | Change (%) | 1-6 | Change (%) | 1-9 | Change (%) | 1-12 | Change (%) | 1-6 | Change (%) | 1-12 | Change (%) |
| | | | YTD | YTD | YTD | YTD | YTD | | YTD | | YTD | | YTD | | Half-year(Actual) | | Full-year | |
| Revenues | 344.8 | 326.9 | 94.7 | 191.7 | 309.7 | 428.9 | 87.1 | -8.0 | 182.4 | -4.9 | 276.1 | -10.8 | - | - | 182.4 | -4.9 | 395.8 | -7.7 |
| Sales | 332.9 | 321.8 | 92.9 | 185.9 | 303.4 | 419.1 | 86.2 | -7.2 | 180.6 | -2.9 | 273.3 | -9.9 | - | - | 180.6 | -2.9 | 390.8 | -6.8 |
| excl. Tamiflu | 294.3 | 313.4 | 72.5 | 160.6 | 247.6 | 342.9 | 75.4 | +4.0 | 168.6 | +5.0 | 257.4 | +4.0 | - | - | 168.6 | +5.0 | 357.8 | +4.3 |
| Tamiflu | 38.7 | 8.4 | 20.4 | 25.4 | 55.8 | 76.2 | 10.8 | -47.1 | 12.0 | -52.8 | 15.8 | -71.7 | - | - | 12.0 | -52.8 | 33.0 | -56.7 |
| Ordinary sales | 10.2 | 7.1 | 6.0 | 11.0 | 18.5 | 36.2 | 1.4 | -76.7 | 1.4 | -87.3 | 1.4 | -92.4 | - | - | 1.4 | -87.3 | 16.4 | -54.7 |
| Govt. stockpile etc. | 28.5 | 1.3 | 14.4 | 14.4 | 37.3 | 40.0 | 9.5 | -34.0 | 10.6 | -26.4 | 14.4 | -61.4 | - | - | 10.6 | -26.4 | 16.6 | -58.5 |
| Other operating revenues | 11.9 | 5.1 | 1.8 | 5.7 | 6.3 | 9.8 | 0.9 | -50.0 | 1.7 | -70.2 | 2.8 | -55.6 | - | - | 1.7 | -70.2 | 5.0 | -49.0 |
| Cost of sales | 137.3 | 127.0 | 43.7 | 83.9 | 143.3 | 192.9 | 41.1 | -5.9 | 80.5 | -4.1 | 119.6 | -16.5 | - | - | 80.5 | -4.1 | 170.8 | -11.5 |
| (% of Sales) | 41.2 | 39.5 | 47.0 | 45.1 | 47.2 | 46.0 | 47.7 | - | 44.6 | - | 43.8 | - | - | - | 44.6 | - | 43.7 | - |
| Gross profit | 207.5 | 199.9 | 51.0 | 107.8 | 166.4 | 236.1 | 46.0 | -9.8 | 101.8 | -5.6 | 156.5 | -5.9 | - | - | 101.8 | -5.6 | 225.0 | -4.7 |
| (% of Revenues) | 60.2 | 61.2 | 53.9 | 56.2 | 53.7 | 55.0 | 52.8 | - | 55.8 | - | 56.7 | - | - | - | 55.8 | - | 56.8 | - |
| SG&A (excl. R&D) expenses | 86.6 | 95.1 | 21.6 | 46.1 | 69.8 | 98.2 | 22.8 | +5.6 | 47.7 | +3.5 | 71.4 | +2.3 | - | - | 47.7 | +3.5 | 100.0 | +1.8 |
| (% of Revenues) | 25.1 | 29.1 | 22.8 | 24.0 | 22.5 | 22.9 | 26.2 | - | 26.2 | - | 25.9 | - | - | - | 26.2 | - | 25.3 | - |
| R&D expenses | 54.2 | 53.2 | 11.8 | 24.5 | 37.8 | 55.3 | 12.2 | +3.4 | 26.6 | +8.6 | 39.9 | +5.6 | - | - | 26.6 | +8.6 | 55.0 | -0.5 |
| (% of Revenues) | 15.7 | 16.3 | 12.5 | 12.8 | 12.2 | 12.9 | 14.0 | - | 14.6 | - | 14.5 | - | - | - | 14.6 | - | 13.9 | - |
| Operating income | 66.7 | 51.6 | 17.5 | 37.2 | 58.8 | 82.6 | 11.1 | -36.6 | 27.6 | -25.8 | 45.1 | -23.3 | - | - | 27.6 | -25.8 | 70.0 | -15.3 |
| (% of Revenues) | 19.3 | 15.8 | 18.5 | 19.4 | 19.0 | 19.3 | 12.7 | - | 15.1 | - | 16.3 | - | - | - | 15.1 | - | 17.7 | - |
| Non-operating income | 4.3 | 9.9 | 5.4 | 6.9 | 7.8 | 9.4 | 1.3 | -75.9 | 3.0 | -56.5 | 2.2 | -71.8 | - | - | 3.0 | -56.5 | - | - |
| Non-operating expenses | 3.3 | 4.2 | 0.2 | 0.6 | 0.5 | 1.6 | 0.3 | +50.0 | 4.4 | +633.3 | 3.0 | +500.0 | - | - | 4.4 | +633.3 | - | - |
| Recurring profit | 67.7 | 57.3 | 22.8 | 43.5 | 66.0 | 90.4 | 12.1 | -46.9 | 26.2 | -39.8 | 44.3 | -32.9 | - | - | 26.2 | -39.8 | 68.7 | -24.0 |
| (% of Revenues) | 19.6 | 17.5 | 24.1 | 22.7 | 21.3 | 21.1 | 13.9 | - | 14.4 | - | 16.0 | - | - | - | 14.4 | - | 17.4 | - |
| Extraordinary gain | 0.3 | 7.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.1 | -66.7 | 0.1 | -66.7 | 0.1 | -66.7 | - | - | 0.1 | -66.7 | - | - |
| Extraordinary loss | 1.6 | 1.4 | 0.0 | 0.1 | 0.1 | 1.3 | 0.0 | - | 0.1 | +0.0 | 0.1 | +0.0 | - | - | 0.1 | +0.0 | - | - |
| Income before income taxes etc. | 66.4 | 63.1 | 23.1 | 43.7 | 66.3 | 89.4 | 12.1 | -47.6 | 26.1 | -40.3 | 44.3 | -33.2 | - | - | 26.1 | -40.3 | - | - |
| (% of Revenues) | 19.3 | 19.3 | 24.4 | 22.8 | 21.4 | 20.8 | 13.9 | - | 14.3 | - | 16.0 | - | - | - | 14.3 | - | - | - |
| Net income | 40.1 | 39.3 | 13.8 | 26.3 | 40.9 | 56.6 | 7.9 | -42.8 | 16.4 | -37.6 | 28.1 | -31.3 | - | - | 16.4 | -37.6 | 43.0 | -24.0 |
| (% of Revenues) | 11.6 | 12.0 | 14.6 | 13.7 | 13.2 | 13.2 | 9.1 | - | 9.0 | - | 10.2 | - | - | - | 9.0 | - | 10.9 | - |

Financial Highlights (QTR)

(Billions of Yen)

| | | | | | | | | | | | | | | | | | Revised Forecasts | | | |
|---------------------------------|--|-----------|-----------|--------|------|-------|--------|------|------------|------|------------|------|------------|-------|------------|------------------|-------------------|----------|------------|--|
| | | FY2007 | FY2008 | FY2009 | | | FY2010 | | | | | | | | | | FY2010 | | | |
| | | 1-12 | 1-12 | 1-3 | 4-6 | 7-9 | 10-12 | 1-3 | Change (%) | 4-6 | Change (%) | 7-9 | Change (%) | 10-12 | Change (%) | 1-6 | Change (%) | 7-12 | Change (%) | |
| | | Full-year | Full-year | QTR | QTR | QTR | QTR | QTR | | QTR | | QTR | | QTR | | 1st Half(Actual) | | 2nd Half | | |
| Revenues | | 344.8 | 326.9 | 94.7 | 97.0 | 118.0 | 119.2 | 87.1 | -8.0 | 95.3 | -1.8 | 93.7 | -20.6 | - | - | 182.4 | -4.9 | 213.4 | -10.1 | |
| Sales | | 332.9 | 321.8 | 92.9 | 93.0 | 117.5 | 115.7 | 86.2 | -7.2 | 94.5 | +1.6 | 92.6 | -21.2 | - | - | 180.6 | -2.9 | 210.2 | -9.9 | |
| excl. Tamiflu | | 294.3 | 313.4 | 72.5 | 88.1 | 87.0 | 95.3 | 75.4 | +4.0 | 93.3 | +5.9 | 88.8 | +2.1 | - | + | 168.6 | +5.0 | 189.2 | +3.8 | |
| Tamiflu | | 38.7 | 8.4 | 20.4 | 5.0 | 30.4 | 20.4 | 10.8 | -47.1 | 1.2 | -76.0 | 3.8 | -87.5 | - | - | 12.0 | -52.8 | 21.0 | -58.7 | |
| Ordinary sales | | 10.2 | 7.1 | 6.0 | 5.0 | 7.6 | 17.7 | 1.4 | -76.7 | 0.0 | -100.0 | 0.0 | -100.0 | - | - | 1.4 | -87.3 | 15.0 | -40.5 | |
| Govt. stockpile etc. | | 28.5 | 1.3 | 14.4 | - | 22.9 | 2.7 | 9.5 | -34.0 | 1.2 | - | 3.8 | -83.4 | - | - | 10.6 | -26.4 | 6.0 | -76.6 | |
| Other operating revenues | | 11.9 | 5.1 | 1.8 | 4.0 | 0.5 | 3.6 | 0.9 | -50.0 | 0.8 | -80.0 | 1.1 | +120.0 | - | - | 1.7 | -70.2 | 3.3 | -19.5 | |
| Cost of sales | | 137.3 | 127.0 | 43.7 | 40.1 | 59.4 | 49.5 | 41.1 | -5.9 | 39.5 | -1.5 | 39.1 | -34.2 | - | - | 80.5 | -4.1 | 90.3 | -17.2 | |
| (% of Sales) | | 41.2 | 39.5 | 47.0 | 43.1 | 50.6 | 42.8 | 47.7 | - | 41.8 | - | 42.2 | - | - | - | 44.6 | - | 43.0 | - | |
| Gross profit | | 207.5 | 199.9 | 51.0 | 56.9 | 58.6 | 69.7 | 46.0 | -9.8 | 55.8 | -1.9 | 54.6 | -6.8 | - | - | 101.8 | -5.6 | 123.2 | -4.0 | |
| (% of Revenues) | | 60.2 | 61.2 | 53.9 | 58.7 | 49.7 | 58.5 | 52.8 | - | 58.6 | - | 58.3 | - | - | - | 55.8 | - | 57.7 | - | |
| SG&A (excl. R&D) expenses | | 86.6 | 95.1 | 21.6 | 24.5 | 23.7 | 28.3 | 22.8 | +5.6 | 24.9 | +1.6 | 23.7 | +0.0 | - | - | 47.7 | +3.5 | 52.3 | +0.6 | |
| (% of Revenues) | | 25.1 | 29.1 | 22.8 | 25.3 | 20.1 | 23.7 | 26.2 | - | 26.1 | - | 25.3 | - | - | - | 26.2 | - | 24.5 | - | |
| R&D expenses | | 54.2 | 53.2 | 11.8 | 12.7 | 13.3 | 17.5 | 12.2 | +3.4 | 14.4 | +13.4 | 13.3 | +0.0 | - | - | 26.6 | +8.6 | 28.4 | -7.8 | |
| (% of Revenues) | | 15.7 | 16.3 | 12.5 | 13.1 | 11.3 | 14.7 | 14.0 | - | 15.1 | - | 14.2 | - | - | - | 14.6 | - | 13.3 | - | |
| Operating income | | 66.7 | 51.6 | 17.5 | 19.6 | 21.6 | 23.8 | 11.1 | -36.6 | 16.5 | -15.8 | 17.6 | -18.5 | - | - | 27.6 | -25.8 | 42.4 | -6.6 | |
| (% of Revenues) | | 19.3 | 15.8 | 18.5 | 20.2 | 18.3 | 20.0 | 12.7 | - | 17.3 | - | 18.8 | - | - | - | 15.1 | - | 19.9 | - | |
| Non-operating income | | 4.3 | 9.9 | 5.4 | 1.5 | 1.2 | 1.7 | 1.3 | -75.9 | 1.7 | +13.3 | 1.6 | +33.3 | - | - | 3.0 | -56.5 | - | - | |
| Non-operating expenses | | 3.3 | 4.2 | 0.2 | 0.5 | 0.2 | 1.1 | 0.3 | +50.0 | 4.1 | +720.0 | 1.1 | +450.0 | - | - | 4.4 | +633.3 | - | - | |
| Recurring profit | | 67.7 | 57.3 | 22.8 | 20.7 | 22.6 | 24.4 | 12.1 | -46.9 | 14.1 | -31.9 | 18.1 | -19.9 | - | - | 26.2 | -39.8 | 42.5 | -9.4 | |
| (% of Revenues) | | 19.6 | 17.5 | 24.1 | 21.3 | 19.2 | 20.5 | 13.9 | - | 14.8 | - | 19.3 | - | - | - | 14.4 | - | 19.9 | - | |
| Extraordinary gain | | 0.3 | 7.3 | 0.3 | - | 0.0 | - | 0.1 | -66.7 | - | - | 0.1 | - | - | - | 0.1 | -66.7 | - | - | |
| Extraordinary loss | | 1.6 | 1.4 | 0.0 | 0.0 | 0.0 | 1.2 | 0.0 | - | 0.0 | - | 0.0 | - | - | - | 0.1 | +0.0 | - | - | |
| Income before income taxes etc. | | 66.4 | 63.1 | 23.1 | 20.6 | 22.6 | 23.2 | 12.1 | -47.6 | 14.1 | -31.6 | 18.2 | -19.5 | - | - | 26.1 | -40.3 | - | - | |
| (% of Revenues) | | 19.3 | 19.3 | 24.4 | 21.2 | 19.2 | 19.5 | 13.9 | - | 14.8 | - | 19.4 | - | - | - | 14.3 | - | - | - | |
| Net income | | 40.1 | 39.3 | 13.8 | 12.5 | 14.6 | 15.7 | 7.9 | -42.8 | 8.5 | -32.0 | 11.7 | -19.9 | - | - | 16.4 | -37.6 | 26.6 | -12.2 | |
| (% of Revenues) | | 11.6 | 12.0 | 14.6 | 12.9 | 12.4 | 13.2 | 9.1 | - | 8.9 | - | 12.5 | - | - | - | 9.0 | - | 12.5 | - | |

Statements of Revenues (YTD)

(Billions of Yen)

| | | | | | | | | | | | | | | | | | Revised Forecasts | | | |
|--|--|--|-----------|-----------|--------|-------|-------|-------|--------|------------|-------|------------|-------|------------|--------|------------|-------------------|------------|-----------|------------|
| | | | FY2007 | FY2008 | FY2009 | | | | FY2010 | | | | | | FY2010 | | | | | |
| | | | 1-12 | 1-12 | 1-3 | 1-6 | 1-9 | 1-12 | 1-3 | Change (%) | 1-6 | Change (%) | 1-9 | Change (%) | 1-12 | Change (%) | 1-6 | Change (%) | 1-12 | Change (%) |
| | | | Full-year | Full-year | YTD | YTD | YTD | YTD | YTD | | YTD | | YTD | | YTD | | Half-year(Actual) | | Full-year | |
| Sales | | | 332.9 | 321.8 | 92.9 | 185.9 | 303.4 | 419.1 | 86.2 | -7.2 | 180.6 | -2.9 | 273.3 | -9.9 | - | - | 180.6 | -2.9 | 390.8 | -6.8 |
| Excl. Tamiflu | | | 294.3 | 313.4 | 72.5 | 160.6 | 247.6 | 342.9 | 75.4 | +4.0 | 168.6 | +5.0 | 257.4 | +4.0 | - | - | 168.6 | +5.0 | 357.8 | +4.3 |
| Domestic | | | 263.1 | 279.9 | 66.2 | 146.3 | 223.9 | 309.3 | 68.0 | +2.7 | 150.6 | +2.9 | 231.3 | +3.3 | - | - | 150.6 | +2.9 | 324.6 | +4.9 |
| Oncology field | | | 74.0 | 102.3 | 25.7 | 57.8 | 88.9 | 123.7 | 28.8 | +12.1 | 64.6 | +11.8 | 100.1 | +12.6 | - | - | 64.6 | +11.8 | 139.9 | +13.1 |
| Avastin *1 | | | 3.5 | 20.1 | 6.7 | 15.4 | 24.3 | 34.9 | 10.3 | +53.7 | 23.3 | +51.3 | 36.8 | +51.4 | - | - | 23.3 | +51.3 | 51.2 | +46.7 |
| Herceptin | | | 16.1 | 23.7 | 6.6 | 14.7 | 22.0 | 29.7 | 5.7 | -13.6 | 12.1 | -17.7 | 18.3 | -16.8 | - | - | 12.1 | -17.7 | 24.7 | -16.8 |
| Rituxan | | | 18.6 | 20.5 | 4.3 | 9.7 | 15.1 | 21.1 | 4.5 | +4.7 | 10.3 | +6.2 | 16.1 | +6.6 | - | - | 10.3 | +6.2 | 22.5 | +6.6 |
| Xeloda | | | 2.7 | 4.8 | 1.3 | 2.8 | 4.4 | 6.6 | 2.3 | +76.9 | 5.1 | +82.1 | 7.8 | +77.3 | - | - | 5.1 | +82.1 | 11.3 | +71.2 |
| Neutrogen | | | 12.6 | 12.0 | 2.2 | 5.2 | 8.2 | 11.3 | 2.0 | -9.1 | 4.6 | -11.5 | 7.2 | -12.2 | - | - | 4.6 | -11.5 | 10.7 | -5.3 |
| Tarceva *1 | | | 0.2 | 4.5 | 1.2 | 2.7 | 4.1 | 5.8 | 1.4 | +16.7 | 3.5 | +29.6 | 5.5 | +34.1 | - | - | 3.5 | +29.6 | 7.7 | +32.8 |
| Kytril | | | 13.6 | 10.9 | 2.1 | 4.5 | 6.6 | 8.6 | 1.5 | -28.6 | 3.0 | -33.3 | 4.3 | -34.8 | - | - | 3.0 | -33.3 | 6.0 | -30.2 |
| Femara | | | 1.0 | 1.7 | 0.5 | 1.1 | 1.7 | 2.4 | 0.6 | +20.0 | 1.4 | +27.3 | 2.2 | +29.4 | - | - | 1.4 | +27.3 | 3.2 | +33.3 |
| Other products | | | 5.6 | 4.1 | 0.8 | 1.7 | 2.5 | 3.3 | 0.6 | -25.0 | 1.3 | -23.5 | 1.9 | -24.0 | - | - | 1.3 | -23.5 | 2.5 | -24.2 |
| Bone and joint diseases field | | | 46.6 | 50.0 | 12.2 | 26.9 | 41.2 | 57.6 | 13.0 | +6.6 | 28.6 | +6.3 | 44.1 | +7.0 | - | - | 28.6 | +6.3 | 63.5 | +10.2 |
| Evista | | | 16.0 | 16.5 | 3.8 | 8.4 | 12.8 | 17.9 | 3.8 | +0.0 | 8.6 | +2.4 | 13.1 | +2.3 | - | - | 8.6 | +2.4 | 18.1 | +1.1 |
| Actemra | | | 0.5 | 3.4 | 1.5 | 3.5 | 5.7 | 8.4 | 2.6 | +73.3 | 5.8 | +65.7 | 9.4 | +64.9 | - | - | 5.8 | +65.7 | 15.1 | +79.8 |
| Suvenyl | | | 11.0 | 12.0 | 2.8 | 6.5 | 10.0 | 13.7 | 2.9 | +3.6 | 6.4 | -1.5 | 9.7 | -3.0 | - | - | 6.4 | -1.5 | 13.9 | +1.5 |
| Alfarol | | | 14.3 | 13.7 | 3.0 | 6.5 | 9.9 | 13.6 | 2.7 | -10.0 | 5.9 | -9.2 | 8.8 | -11.1 | - | - | 5.9 | -9.2 | 12.5 | -8.1 |
| Other products | | | 4.8 | 4.5 | 1.1 | 2.1 | 2.8 | 3.9 | 1.0 | -9.1 | 1.9 | -9.5 | 3.1 | +10.7 | - | - | 1.9 | -9.5 | 4.0 | +2.6 |
| Renal diseases field | | | 69.6 | 61.3 | 13.0 | 28.8 | 44.4 | 61.0 | 12.5 | -3.8 | 27.2 | -5.6 | 41.7 | -6.1 | - | - | 27.2 | -5.6 | 58.3 | -4.4 |
| Epogin | | | 54.8 | 44.9 | 9.4 | 20.8 | 32.3 | 44.4 | 8.7 | -7.4 | 19.0 | -8.7 | 29.2 | -9.6 | - | - | 19.0 | -8.7 | 41.2 | -7.2 |
| Oxarol | | | 8.7 | 10.0 | 2.2 | 4.9 | 7.7 | 10.6 | 2.5 | +13.6 | 5.6 | +14.3 | 8.6 | +11.7 | - | - | 5.6 | +14.3 | 11.6 | +9.4 |
| Renagel | | | 5.6 | 5.7 | 1.3 | 2.7 | 4.0 | 5.3 | 1.1 | -15.4 | 2.3 | -14.8 | 3.5 | -12.5 | - | - | 2.3 | -14.8 | 4.9 | -7.5 |
| Other products | | | 0.5 | 0.7 | 0.2 | 0.4 | 0.5 | 0.7 | 0.2 | +0.0 | 0.3 | -25.0 | 0.4 | -20.0 | - | - | 0.3 | -25.0 | 0.7 | +0.0 |
| Transplant, Immunology & Infectious diseases field | | | 17.7 | 24.0 | 5.9 | 12.8 | 19.3 | 26.2 | 5.3 | -10.2 | 11.9 | -7.0 | 18.3 | -5.2 | - | - | 11.9 | -7.0 | 25.8 | -1.5 |
| Pegasys | | | 6.3 | 9.7 | 2.5 | 5.5 | 8.2 | 11.1 | 2.2 | -12.0 | 4.8 | -12.7 | 7.4 | -9.8 | - | - | 4.8 | -12.7 | 10.5 | -5.4 |
| Copegus *1 | | | 2.0 | 4.2 | 1.1 | 2.4 | 3.6 | 4.9 | 0.9 | -18.2 | 2.0 | -16.7 | 3.1 | -13.9 | - | - | 2.0 | -16.7 | 4.6 | -6.1 |
| Rocephin | | | 5.7 | 5.9 | 1.3 | 2.7 | 4.1 | 5.5 | 1.1 | -15.4 | 2.6 | -3.7 | 3.9 | -4.9 | - | - | 2.6 | -3.7 | 5.4 | -1.8 |
| CellCept | | | 3.5 | 4.0 | 0.9 | 2.1 | 3.2 | 4.4 | 1.0 | +11.1 | 2.3 | +9.5 | 3.6 | +12.5 | - | - | 2.3 | +9.5 | 5.0 | +13.6 |
| Other products | | | 0.3 | 0.3 | 0.1 | 0.1 | 0.2 | 0.3 | 0.1 | +0.0 | 0.1 | +0.0 | 0.2 | +0.0 | - | - | 0.1 | +0.0 | 0.3 | +0.0 |
| Others field | | | 55.1 | 42.3 | 9.4 | 20.0 | 30.1 | 40.9 | 8.3 | -11.7 | 18.3 | -8.5 | 27.1 | -10.0 | - | - | 18.3 | -8.5 | 37.1 | -9.3 |
| Sigmart | | | 15.2 | 15.0 | 3.3 | 7.1 | 10.6 | 14.7 | 2.9 | -12.1 | 6.3 | -11.3 | 9.4 | -11.3 | - | - | 6.3 | -11.3 | 13.1 | -10.9 |
| SA products *2 | | | 11.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other products | | | 28.8 | 27.3 | 6.2 | 13.0 | 19.4 | 26.3 | 5.4 | -12.9 | 12.0 | -7.7 | 17.7 | -8.8 | - | - | 12.0 | -7.7 | 24.0 | -8.7 |
| Overseas | | | 31.2 | 33.5 | 6.3 | 14.2 | 23.7 | 33.6 | 7.4 | +17.5 | 18.1 | +27.5 | 26.1 | +10.1 | - | - | 18.1 | +27.5 | 33.2 | -1.2 |
| Neutrogen | | | 26.6 | 25.9 | 4.8 | 10.2 | 15.8 | 21.3 | 4.4 | -8.3 | 8.8 | -13.7 | 13.0 | -17.7 | - | - | 8.8 | -13.7 | 17.0 | -20.2 |
| Actemra | | | - | 3.8 | 0.4 | 1.8 | 5.1 | 8.9 | 2.0 | +400.0 | 7.4 | +311.1 | 10.5 | +105.9 | - | - | 7.4 | +311.1 | 12.8 | +43.8 |
| Sigmart | | | 2.8 | 2.0 | 0.6 | 1.3 | 1.5 | 1.9 | 0.8 | +33.3 | 1.3 | +0.0 | 1.8 | +20.0 | - | - | 1.3 | +0.0 | 2.2 | +15.8 |
| Other products | | | 1.9 | 1.7 | 0.5 | 1.0 | 1.2 | 1.5 | 0.2 | -60.0 | 0.5 | -50.0 | 0.8 | -33.3 | - | - | 0.5 | -50.0 | 1.2 | -20.0 |
| Tamiflu | | | 38.7 | 8.4 | 20.4 | 25.4 | 55.8 | 76.2 | 10.8 | -47.1 | 12.0 | -52.8 | 15.8 | -71.7 | - | - | 12.0 | -52.8 | 33.0 | -56.7 |
| Ordinary sales | | | 10.2 | 7.1 | 6.0 | 11.0 | 18.5 | 36.2 | 1.4 | -76.7 | 1.4 | -87.3 | 1.4 | -92.4 | - | - | 1.4 | -87.3 | 16.4 | -54.7 |
| Govt. stockpile etc. | | | 28.5 | 1.3 | 14.4 | 14.4 | 37.3 | 40.0 | 9.5 | -34.0 | 10.6 | -26.4 | 14.4 | -61.4 | - | - | 10.6 | -26.4 | 16.6 | -58.5 |
| Other operating revenues | | | 11.9 | 5.1 | 1.8 | 5.7 | 6.3 | 9.8 | 0.9 | -50.0 | 1.7 | -70.2 | 2.8 | -55.6 | - | - | 1.7 | -70.2 | 5.0 | -49.0 |
| Revenues (total) | | | 344.8 | 326.9 | 94.7 | 191.7 | 309.7 | 428.9 | 87.1 | -8.0 | 182.4 | -4.9 | 276.1 | -10.8 | - | - | 182.4 | -4.9 | 395.8 | -7.7 |
| Domestic | | | 308.4 | 293.1 | 86.7 | 175.5 | 283.7 | 392.6 | 78.9 | -9.0 | 162.8 | -7.2 | 247.5 | -12.8 | - | - | 162.8 | -7.2 | 358.0 | -8.8 |
| Overseas | | | 36.4 | 33.8 | 8.0 | 16.2 | 26.1 | 36.4 | 8.2 | +2.5 | 19.6 | +21.0 | 28.6 | +9.6 | - | - | 19.6 | +21.0 | 37.8 | +3.8 |

Notes: 1. The products marketed in 2007 and subsequent years are as follows: Avastin (launched in June 2007), Tarceva (December 2007), Copegus (March 2007).
2. Sales of the products for which the marketing collaboration in Japan with sanofi-aventis K.K. ended on December 31, 2007, are included in the "Others field (SA products)."

Statements of Revenues (QTR)

(Billions of Yen)

| | | | | | | | | | | | | | | | | Revised Forecasts | | | |
|--|--|-----------|-----------|--------|------|-------|-------|--------|------------|------|------------|------|------------|-------|------------|-------------------|------------|----------|------------|
| | | FY2007 | FY2008 | FY2009 | | | | FY2010 | | | | | | | | FY2010 | | | |
| | | 1-12 | 1-12 | 1-3 | 4-6 | 7-9 | 10-12 | 1-3 | Change (%) | 4-6 | Change (%) | 7-9 | Change (%) | 10-12 | Change (%) | 1-6 | Change (%) | 7-12 | Change (%) |
| | | Full-year | Full-year | QTR | QTR | QTR | QTR | QTR | | QTR | | QTR | | QTR | | 1st Half(Actual) | | 2nd Half | |
| Sales | | 332.9 | 321.8 | 92.9 | 93.0 | 117.5 | 115.7 | 86.2 | -7.2 | 94.5 | +1.6 | 92.6 | -21.2 | - | - | 180.6 | -2.9 | 210.2 | -9.9 |
| Excl. Tamiflu | | 294.3 | 313.4 | 72.5 | 88.1 | 87.0 | 95.3 | 75.4 | +4.0 | 93.3 | +5.9 | 88.8 | +2.1 | - | - | 168.6 | +5.0 | 189.2 | +3.8 |
| Domestic | | 263.1 | 279.9 | 66.2 | 80.1 | 77.6 | 85.4 | 68.0 | +2.7 | 82.6 | +3.1 | 80.8 | +4.1 | - | - | 150.6 | +2.9 | 174.1 | +6.8 |
| Oncology field | | 74.0 | 102.3 | 25.7 | 32.1 | 31.1 | 34.8 | 28.8 | +12.1 | 35.7 | +11.2 | 35.5 | +14.1 | - | - | 64.6 | +11.8 | 75.4 | +14.4 |
| Avastin | | 3.5 | 20.1 | 6.7 | 8.6 | 8.9 | 10.6 | 10.3 | +53.7 | 13.0 | +51.2 | 13.5 | +51.7 | - | - | 23.3 | +51.3 | 27.9 | +43.1 |
| Herceptin | | 16.1 | 23.7 | 6.6 | 8.1 | 7.3 | 7.7 | 5.7 | -13.6 | 6.4 | -21.0 | 6.2 | -15.1 | - | - | 12.1 | -17.7 | 12.6 | -16.0 |
| Rituxan | | 18.6 | 20.5 | 4.3 | 5.5 | 5.4 | 5.9 | 4.5 | +4.7 | 5.8 | +5.5 | 5.8 | +7.4 | - | - | 10.3 | +6.2 | 12.2 | +8.0 |
| Xeloda | | 2.7 | 4.8 | 1.3 | 1.5 | 1.6 | 2.2 | 2.3 | +76.9 | 2.8 | +86.7 | 2.7 | +68.8 | - | - | 5.1 | +82.1 | 6.2 | +63.2 |
| Neutrogen | | 12.6 | 12.0 | 2.2 | 3.0 | 3.0 | 3.1 | 2.0 | -9.1 | 2.6 | -13.3 | 2.6 | -13.3 | - | - | 4.6 | -11.5 | 6.1 | +0.0 |
| Tarceva | | 0.2 | 4.5 | 1.2 | 1.5 | 1.4 | 1.7 | 1.4 | +16.7 | 2.0 | +33.3 | 2.0 | +42.9 | - | - | 3.5 | +29.6 | 4.3 | +43.3 |
| Kytril | | 13.6 | 10.9 | 2.1 | 2.4 | 2.1 | 2.1 | 1.5 | -28.6 | 1.5 | -37.5 | 1.3 | -38.1 | - | - | 3.0 | -33.3 | 3.0 | -28.6 |
| Femara | | 1.0 | 1.7 | 0.5 | 0.6 | 0.6 | 0.7 | 0.6 | +20.0 | 0.8 | +33.3 | 0.8 | +33.3 | - | - | 1.4 | +27.3 | 1.8 | +28.6 |
| Other products | | 5.6 | 4.1 | 0.8 | 0.9 | 0.8 | 0.8 | 0.6 | -25.0 | 0.7 | -22.2 | 0.6 | -25.0 | - | - | 1.3 | -23.5 | 1.2 | -25.0 |
| Bone and joint diseases field | | 46.6 | 50.0 | 12.2 | 14.8 | 14.3 | 16.4 | 13.0 | +6.6 | 15.7 | +6.1 | 15.4 | +7.7 | - | - | 28.6 | +6.3 | 34.9 | +13.7 |
| Evista | | 16.0 | 16.5 | 3.8 | 4.6 | 4.4 | 5.1 | 3.8 | +0.0 | 4.8 | +4.3 | 4.5 | +2.3 | - | - | 8.6 | +2.4 | 9.5 | -1.0 |
| Actemra | | 0.5 | 3.4 | 1.5 | 2.0 | 2.2 | 2.7 | 2.6 | +73.3 | 3.3 | +65.0 | 3.6 | +63.6 | - | - | 5.8 | +65.7 | 9.2 | +87.8 |
| Suvenyl | | 11.0 | 12.0 | 2.8 | 3.7 | 3.5 | 3.7 | 2.9 | +3.6 | 3.5 | -5.4 | 3.3 | -5.7 | - | - | 6.4 | -1.5 | 7.5 | +4.2 |
| Alfarol | | 14.3 | 13.7 | 3.0 | 3.5 | 3.3 | 3.7 | 2.7 | -10.0 | 3.2 | -8.6 | 2.9 | -12.1 | - | - | 5.9 | -9.2 | 6.7 | -5.6 |
| Other products | | 4.8 | 4.5 | 1.1 | 1.0 | 0.8 | 1.1 | 1.0 | -9.1 | 0.9 | -10.0 | 1.1 | +37.5 | - | - | 1.9 | -9.5 | 2.0 | +5.3 |
| Renal diseases field | | 69.6 | 61.3 | 13.0 | 15.8 | 15.6 | 16.5 | 12.5 | -3.8 | 14.7 | -7.0 | 14.6 | -6.4 | - | - | 27.2 | -5.6 | 31.1 | -3.4 |
| Epogin | | 54.8 | 44.9 | 9.4 | 11.5 | 11.4 | 12.1 | 8.7 | -7.4 | 10.3 | -10.4 | 10.2 | -10.5 | - | - | 19.0 | -8.7 | 22.2 | -5.9 |
| Oxarol | | 8.7 | 10.0 | 2.2 | 2.8 | 2.7 | 2.9 | 2.5 | +13.6 | 3.1 | +10.7 | 3.0 | +11.1 | - | - | 5.6 | +14.3 | 6.0 | +5.3 |
| Renagel | | 5.6 | 5.7 | 1.3 | 1.4 | 1.3 | 1.3 | 1.1 | -15.4 | 1.2 | -14.3 | 1.2 | -7.7 | - | - | 2.3 | -14.8 | 2.6 | +0.0 |
| Other products | | 0.5 | 0.7 | 0.2 | 0.1 | 0.2 | 0.1 | 0.2 | +0.0 | 0.1 | +0.0 | 0.1 | -50.0 | - | - | 0.3 | -25.0 | 0.3 | +0.0 |
| Transplant, Immunology & Infectious diseases field | | 17.7 | 24.0 | 5.9 | 6.9 | 6.5 | 6.8 | 5.3 | -10.2 | 6.6 | -4.3 | 6.4 | -1.5 | - | - | 11.9 | -7.0 | 13.9 | +4.5 |
| Pegasys | | 6.3 | 9.7 | 2.5 | 2.9 | 2.8 | 2.9 | 2.2 | -12.0 | 2.6 | -10.3 | 2.6 | -7.1 | - | - | 4.8 | -12.7 | 5.7 | +1.8 |
| Copegus | | 2.0 | 4.2 | 1.1 | 1.3 | 1.2 | 1.2 | 0.9 | -18.2 | 1.1 | -15.4 | 1.1 | -8.3 | - | - | 2.0 | -16.7 | 2.5 | +4.2 |
| Rocephin | | 5.7 | 5.9 | 1.3 | 1.5 | 1.4 | 1.4 | 1.1 | -15.4 | 1.5 | +0.0 | 1.4 | +0.0 | - | - | 2.6 | -3.7 | 2.9 | +7.4 |
| CellCept | | 3.5 | 4.0 | 0.9 | 1.1 | 1.1 | 1.2 | 1.0 | +11.1 | 1.3 | +18.2 | 1.3 | +18.2 | - | - | 2.3 | +9.5 | 2.6 | +8.3 |
| Other products | | 0.3 | 0.3 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | +0.0 | 0.1 | +0.0 | 0.1 | +0.0 | - | - | 0.1 | +0.0 | 0.1 | -50.0 |
| Others field | | 55.1 | 42.3 | 9.4 | 10.6 | 10.0 | 10.9 | 8.3 | -11.7 | 9.9 | -6.6 | 8.8 | -12.0 | - | - | 18.3 | -8.5 | 18.8 | -10.0 |
| Sigmat | | 15.2 | 15.0 | 3.3 | 3.8 | 3.6 | 4.0 | 2.9 | -12.1 | 3.4 | -10.5 | 3.0 | -16.7 | - | - | 6.3 | -11.3 | 6.7 | -11.8 |
| SA products | | 11.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other products | | 28.8 | 27.3 | 6.2 | 6.8 | 6.5 | 6.8 | 5.4 | -12.9 | 6.5 | -4.4 | 5.8 | -10.8 | - | - | 12.0 | -7.7 | 12.1 | -9.0 |
| Overseas | | 31.2 | 33.5 | 6.3 | 7.9 | 9.5 | 9.9 | 7.4 | +17.5 | 10.7 | +35.4 | 8.0 | -15.8 | - | - | 18.1 | +27.5 | 15.1 | -22.2 |
| Neutrogen | | 26.6 | 25.9 | 4.8 | 5.4 | 5.6 | 5.5 | 4.4 | -8.3 | 4.4 | -18.5 | 4.2 | -25.0 | - | - | 8.8 | -13.7 | 8.2 | -26.1 |
| Actemra | | - | 3.8 | 0.4 | 1.4 | 3.3 | 3.8 | 2.0 | +400.0 | 5.4 | +285.7 | 3.1 | -6.1 | - | - | 7.4 | +311.1 | 5.4 | -23.9 |
| Sigmat | | 2.8 | 2.0 | 0.6 | 0.6 | 0.3 | 0.4 | 0.8 | +33.3 | 0.6 | +0.0 | 0.4 | +33.3 | - | - | 1.3 | +0.0 | 0.9 | +28.6 |
| Other products | | 1.9 | 1.7 | 0.5 | 0.5 | 0.2 | 0.2 | 0.2 | -60.0 | 0.3 | -40.0 | 0.3 | +50.0 | - | - | 0.5 | -50.0 | 0.7 | +40.0 |
| Tamiflu | | 38.7 | 8.4 | 20.4 | 5.0 | 30.4 | 20.4 | 10.8 | -47.1 | 1.2 | -76.0 | 3.8 | -87.5 | - | - | 12.0 | -52.8 | 21.0 | -58.7 |
| Ordinary sales | | 10.2 | 7.1 | 6.0 | 5.0 | 7.6 | 17.7 | 1.4 | -76.7 | 0.0 | -100.0 | 0.0 | -100.0 | - | - | 1.4 | -87.3 | 15.0 | -40.5 |
| Govt. stockpile etc. | | 28.5 | 1.3 | 14.4 | - | 22.9 | 2.7 | 9.5 | -34.0 | 1.2 | - | 3.8 | -83.4 | - | - | 10.6 | -26.4 | 6.0 | -76.6 |
| Other operating revenues | | 11.9 | 5.1 | 1.8 | 4.0 | 0.5 | 3.6 | 0.9 | -50.0 | 0.8 | -80.0 | 1.1 | +120.0 | - | - | 1.7 | -70.2 | 3.3 | -19.5 |
| Revenues (total) | | 344.8 | 326.9 | 94.7 | 97.0 | 118.0 | 119.2 | 87.1 | -8.0 | 95.3 | -1.8 | 93.7 | -20.6 | - | - | 182.4 | -4.9 | 213.4 | -10.1 |
| Domestic | | 308.4 | 293.1 | 86.7 | 88.8 | 108.1 | 108.9 | 78.9 | -9.0 | 83.9 | -5.5 | 84.7 | -21.6 | - | - | 162.8 | -7.2 | 195.2 | -10.0 |
| Overseas | | 36.4 | 33.8 | 8.0 | 8.2 | 9.9 | 10.3 | 8.2 | +2.5 | 11.4 | +39.0 | 9.0 | -9.1 | - | - | 19.6 | +21.0 | 18.2 | -9.9 |

Balance Sheets

(Billions of Yen)

| | FY2007 | FY2008 | FY2009 | | | | FY2010 | | | | | |
|--|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|-------------------|-------------------|------------------|
| | As of Dec. 31 | As of Dec. 31 | As of Mar. 31 | As of Jun. 30 | As of Sep. 30 | As of Dec. 31 | As of Mar. 31 | As of Jun. 30 | As of Sep. 30 | vs. Sep. 30, 2009 | vs. Dec. 31, 2009 | As of Dec. 31 |
| Cash and deposits | 73.2 | 70.8 | 77.6 | 90.8 | 77.6 | 107.0 | 101.1 | 81.3 | 70.2 | -7.4 | -36.8 | - |
| Trade notes and accounts receivable | 107.0 | 108.5 | 111.3 | 102.7 | 121.8 | 121.6 | 85.4 | 99.2 | 99.3 | -22.5 | -22.3 | - |
| Marketable securities | 65.5 | 54.7 | 46.0 | 54.5 | 55.6 | 52.2 | 55.7 | 61.7 | 58.7 | 3.1 | 6.5 | - |
| Inventories | 55.2 | 78.7 | 78.7 | 94.0 | 90.4 | 92.6 | 100.0 | 111.7 | 115.9 | 25.5 | 23.3 | - |
| Other current assets | 28.9 | 31.7 | 34.3 | 30.9 | 32.3 | 37.9 | 41.7 | 29.5 | 35.0 | 2.7 | -2.9 | - |
| Total Current assets | 329.8 | 344.4 | 347.9 | 372.9 | 377.7 | 411.3 | 383.9 | 383.4 | 379.1 | 1.4 | -32.2 | - |
| Property, plant and equipment | 92.5 | 98.3 | 97.1 | 96.2 | 93.7 | 93.7 | 91.4 | 89.8 | 88.4 | -5.3 | -5.3 | - |
| Intangible assets | 3.7 | 3.1 | 3.2 | 3.0 | 2.7 | 3.2 | 3.0 | 2.6 | 2.6 | -0.1 | -0.6 | - |
| Investments and other assets | 32.9 | 32.7 | 30.6 | 29.6 | 31.2 | 32.3 | 32.9 | 31.4 | 31.1 | -0.1 | -1.2 | - |
| thereof Investment securities | 16.8 | 14.4 | 11.8 | 10.6 | 9.8 | 9.7 | 9.5 | 8.0 | 7.3 | -2.5 | -2.4 | - |
| Total Noncurrent Assets | 129.1 | 134.2 | 130.9 | 128.8 | 127.6 | 129.2 | 127.2 | 123.8 | 122.1 | -5.5 | -7.1 | - |
| Total Assets | 458.9 | 478.5 | 478.7 | 501.7 | 505.3 | 540.5 | 511.1 | 507.2 | 501.2 | -4.1 | -39.3 | - |
| Trade notes and accounts payable | 17.3 | 28.8 | 34.0 | 37.8 | 34.3 | 34.3 | 35.4 | 32.2 | 26.2 | -8.1 | -8.1 | - |
| Short-term loans and bonds | 0.3 | - | - | - | - | - | - | - | - | - | - | - |
| Other current liabilities | 52.1 | 49.8 | 41.4 | 44.7 | 49.0 | 66.2 | 42.2 | 36.3 | 33.2 | -15.8 | -33.0 | - |
| Total current liabilities | 69.8 | 78.5 | 75.4 | 82.5 | 83.3 | 100.5 | 77.6 | 68.5 | 59.4 | -23.9 | -41.1 | - |
| Long-term debt and bonds | - | - | - | - | - | - | - | - | - | - | - | - |
| Other noncurrent liabilities | 3.3 | 2.9 | 3.0 | 3.3 | 3.6 | 5.4 | 5.2 | 4.8 | 5.0 | 1.4 | -0.4 | - |
| Total noncurrent liabilities | 3.3 | 2.9 | 3.0 | 3.3 | 3.6 | 5.4 | 5.2 | 4.8 | 5.0 | 1.4 | -0.4 | - |
| Total liabilities | 73.1 | 81.5 | 78.4 | 85.8 | 86.9 | 105.9 | 82.8 | 73.3 | 64.4 | -22.5 | -41.5 | - |
| Common stock | 72.9 | 73.0 | 73.0 | 73.0 | 73.0 | 73.0 | 73.0 | 73.0 | 73.0 | - | - | - |
| Additional paid-in capital | 92.8 | 92.8 | 92.8 | 92.8 | 92.8 | 92.8 | 92.8 | 92.8 | 92.8 | - | - | - |
| Retained earnings | 248.1 | 271.0 | 274.4 | 286.9 | 292.3 | 308.0 | 303.3 | 311.8 | 314.3 | 22.0 | 6.3 | - |
| Treasury stock, at cost | -35.1 | -35.2 | -35.2 | -35.2 | -36.3 | -36.3 | -36.3 | -36.3 | -36.3 | 0.0 | 0.0 | - |
| Net unrealized gain on securities | 2.8 | 1.4 | 0.9 | 2.0 | 1.7 | 1.6 | 1.8 | 1.5 | 1.2 | -0.5 | -0.4 | - |
| Foreign currency translation adjustments | 1.9 | -7.9 | -7.3 | -5.8 | -6.9 | -6.8 | -8.2 | -11.1 | -10.1 | -3.2 | -3.3 | - |
| New share warrants | 0.1 | 0.3 | 0.4 | 0.4 | 0.5 | 0.5 | 0.6 | 0.6 | 0.7 | 0.2 | 0.2 | - |
| Minority interests | 2.2 | 1.7 | 1.3 | 1.8 | 1.4 | 1.8 | 1.3 | 1.4 | 1.2 | -0.2 | -0.6 | - |
| Total net assets | 385.8 | 397.1 | 400.4 | 416.0 | 418.4 | 434.7 | 428.4 | 433.9 | 436.7 | 18.3 | 2.0 | - |
| Total liabilities and net assets | 458.9 | 478.5 | 478.7 | 501.7 | 505.3 | 540.5 | 511.1 | 507.2 | 501.2 | -4.1 | -39.3 | - |

Cash Flows

(Billions of Yen)

| | FY2007 | FY2008 | FY2009 | | | | FY2010 | | | |
|--|-----------|-----------|--------|-------|-------|-----------|--------|-------|-------|-----------|
| | 1-12 | 1-12 | 1-3 | 1-6 | 1-9 | 1-12 | 1-3 | 1-6 | 1-9 | 1-12 |
| | Full-year | Full-year | YTD | YTD | YTD | Full-year | YTD | YTD | YTD | Full-year |
| | | | | | | | | | | |
| Net cash provided by (used in) operating activities | 60.4 | 39.3 | 13.0 | 33.7 | 36.9 | 66.5 | 16.4 | 6.8 | 4.4 | - |
| Net cash provided by (used in) investing activities | -7.5 | -14.1 | -3.9 | -13.3 | -21.6 | -20.3 | 1.2 | -16.6 | -16.2 | - |
| Net cash provided by (used in) financing activities | -47.2 | -18.4 | -11.0 | -11.0 | -22.3 | -22.3 | -13.2 | -13.2 | -23.1 | - |
| Effect of exchange rate changes on cash and cash equivalents | -0.3 | -9.9 | -0.6 | 0.6 | 1.0 | -0.1 | -0.6 | -1.5 | -1.2 | - |
| Net increase (decrease) in cash and cash equivalents | 5.4 | -3.1 | -2.5 | 9.9 | -6.1 | 23.8 | 3.8 | -24.5 | -36.1 | - |
| Cash and cash equivalents at beginning of period | 68.3 | 73.7 | 70.7 | 70.7 | 70.7 | 70.7 | 94.5 | 94.5 | 94.5 | - |
| Cash and cash equivalents at end of period | 73.7 | 70.7 | 68.1 | 80.6 | 64.6 | 94.5 | 98.2 | 69.9 | 58.4 | - |

Performance Indicators

| | FY2007 | FY2008 | FY2009 | | | | FY2010 | | | | Revised Forecast |
|--------------------------------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|------------------|
| | 1-12 | 1-12 | 1-3 | 1-6 | 1-9 | 1-12 | 1-3 | 1-6 | 1-9 | 1-12 | FY2010 |
| | As of Dec. 31 | As of Dec. 31 | As of Mar. 31 | As of Jun. 30 | As of Sep. 30 | As of Dec. 31 | As of Mar. 31 | As of Jun. 30 | As of Sep. 30 | As of Dec. 31 | As of Dec. 31 |
| | | | | | | | | | | | |
| Net income per share (Basic) | 73.23yen | 72.07yen | 25.27yen | 48.29yen | 75.07yen | 104.00yen | 14.43yen | 30.09yen | 51.55yen | - | 79.02yen |
| Net income per share (Fully diluted) | 73.16yen | 72.04yen | 25.27yen | 48.28yen | 75.06yen | 103.98yen | 14.43yen | 30.09yen | 51.54yen | - | - |
| Return on equity (ROE)* | 10.4% | 10.1% | 3.5% | 6.5% | 10.1% | 13.7% | 1.8% | 3.8% | 6.5% | - | - |
| Return on assets (ROA)* | 14.7% | 12.2% | 4.8% | 8.9% | 13.4% | 17.7% | 2.3% | 5.0% | 8.5% | - | - |
| Net assets per share | 703.80yen | 725.18yen | 731.74yen | 759.41yen | 765.47yen | 794.51yen | 783.67yen | 793.50yen | 799.11yen | - | - |
| Equity ratio | 83.5% | 82.6% | 83.3% | 82.5% | 82.4% | 80.0% | 83.4% | 85.1% | 86.8% | - | - |
| Dividends per share (Annual) | 30yen | 34yen | | | | 40yen | | | | - | 34yen |
| Dividends per share (Interim) | 15yen | 15yen | | | | 17yen | | | | 17yen | 17yen |
| Payout ratio | 41.0% | 47.2% | | | | 38.5% | | | | - | 43.0% |

Note: Quarterly (year-to-date) ROE and ROA are not annualized.

Number of Employees

| | FY2007 | FY2008 | FY2009 | | | | FY2010 | | | | Revised Forecast |
|---------------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|------------------|
| | 1-12 | 1-12 | 1-3 | 1-6 | 1-9 | 1-12 | 1-3 | 1-6 | 1-9 | 1-12 | FY2010 |
| | As of Dec. 31 | As of Dec. 31 | As of Mar. 31 | As of Jun. 30 | As of Sep. 30 | As of Dec. 31 | As of Mar. 31 | As of Jun. 30 | As of Sep. 30 | As of Dec. 31 | As of Dec. 31 |
| | | | | | | | | | | | |
| Number of employees | 6,257 | 6,383 | 6,347 | 6,474 | 6,481 | 6,485 | 6,472 | 6,707 | 6,723 | - | 6,760 |

Note: Number of employees doesn't include staff seconded to companies outside the Group.

Capital Expenditures

(Billions of Yen)

| | FY2007 | FY2008 | FY2009 | | | | FY2010 | | | | Revised Forecast |
|----------------------|-----------|-----------|--------|-----|------|-----------|--------|-----|------|-----------|------------------|
| | 1-12 | 1-12 | 1-3 | 1-6 | 1-9 | 1-12 | 1-3 | 1-6 | 1-9 | 1-12 | FY2010 |
| | Full-year | Full-year | YTD | YTD | YTD | Full-year | YTD | YTD | YTD | Full-year | Full-year |
| | | | | | | | | | | | |
| Capital expenditures | 19.6 | 26.6 | 2.8 | 6.6 | 9.1 | 14.6 | 1.8 | 4.6 | 7.9 | - | 14.0 |
| Depreciation | 13.3 | 19.4 | 4.2 | 8.9 | 14.1 | 19.5 | 4.1 | 8.4 | 13.0 | - | 18.0 |

Development pipeline (as of October 22, 2010)

| Development code | Indication # Additional indication | Stage (date) | Generic name Product name Dosage form | Origin Overseas name (Collaborator) | Mode of Action |
|------------------------|--|----------------------------------|---|---|---|
| <u>Oncology</u> | | | | | |
| RG435 | Breast cancer # | Filed Oct. 09 | bevacizumab Avastin Injection | Roche Avastin | Humanized anti-VEGF(Vascular Endothelial Growth Factor) monoclonal antibody |
| | Colon cancer (adjuvant) # | Phase III Multinational study | | | |
| | Gastric cancer # | Phase III Multinational study | | | |
| | Breast cancer (adjuvant) # | Phase III Multinational study | | | |
| | Glioblastoma # | Phase III Multinational study | | | |
| | Glioblastoma (relapsed) # | Phase II | | | |
| | | | | | |
| EPOCH | Chemotherapy-induced anemia # | Filed Nov. 09 | epoetin beta Epogin Injection | In-house | Recombinant human erythropoietin |
| RG340 | Gastric cancer # | Filed Mar. 10 | capecitabine Xeloda Oral | Roche Xeloda | Antimetabolite, 5-FU derivative |
| RG597 | Gastric cancer # | Filed Mar. 10 | trastuzumab Herceptin Injection | Roche Herceptin | Humanized anti-HER2 monoclonal antibody |
| RG1415 | Pancreatic cancer # | Filed Sep. 09 | erlotinib Tarceva | Roche/OSI Tarceva | EGFR tyrosine kinase inhibitor |
| | Non-small cell lung cancer (1st line) # | Phase II | Oral | | |
| RG1273 | Breast cancer | Phase III Multinational study | pertuzumab Injection | Roche | Humanized HER dimerization inhibitory monoclonal antibody |
| TP300 | Gastric cancer, etc | Phase II Overseas | Injection | In-house | Topoisomerase I inhibitor |

| Development code | Indication # Additional indication | Stage (date) | Generic name Product name Dosage form | Origin Overseas name (Collaborator) | Mode of Action |
|---------------------------------------|---|------------------------------|--|---|--|
| RG3502 | Breast cancer | Phase II | Injection | Roche | HER2 antibody-drug conjugate |
| MRA | Pancreatic cancer # | Phase I / II | tocilizumab Actemra Injection | In-house (Roche) | Humanized anti-human IL-6 receptor monoclonal antibody |
| AF802 | Non-small cell lung cancer | Phase I / II | Oral | In-house | ALK inhibitor |
| CIF (RG7167) | Solid tumors | Phase I | Oral | In-house | MEK inhibitor |
| | | Phase I Overseas | | (Roche) | |
| CKI27 (RG7304) | Solid tumors | Phase I | Oral | In-house | Raf and MEK dual inhibitor |
| | | Phase I Overseas | | (Roche) | |
| GC33 | Liver cancer | Phase I Overseas | Injection | In-house | Humanized anti-Glypican-3 monoclonal antibody |
| PA799 | Solid tumors | Phase I Overseas | Oral | In-house | - |
| GA101 (RG7159) | Non-Hodgkin's lymphoma | Phase I | Injection | GlycArt | Humanized anti-CD20 monoclonal antibody |
| <u>Bone and Joint diseases</u> | | | | | |
| ED-71 | Osteoporosis | Filed Oct. 09 | eldecalcitol Oral | In-house (Taisho Pharmaceutical) | Active Vitamin D ₃ derivative |
| MRA | Systemic onset juvenile idiopathic arthritis (sJIA) # | Filed Oct. 10 Overseas | tocilizumab Actemra / RoActemra(EU) Injection | In-house (Roche) | Humanized anti-human IL-6 receptor monoclonal antibody |

| Development code | Indication # Additional indication | Stage (date) | Generic name Product name Dosage form | Origin Overseas name (Collaborator) | Mode of Action |
|--|--|---------------------------------|---|---|---|
| | Rheumatoid arthritis (new formulation: subcutaneous injection) | Phase III | tocilizumab Actemra Injection | | |
| RG1594 | Rheumatoid arthritis | Development suspended | ocrelizumab Injection | Roche | Humanized anti-CD20 monoclonal antibody |
| RG484 | Osteoporosis | Phase II / III | ibandronate sodium hydrate Injection | Roche Boniva (US) / Bonviva (EU) (Taisho Pharmaceutical) | Bisphosphonate |
| | | Phase II | ibandronate sodium hydrate Oral | | |
| Renal diseases | | | | | |
| RG744 | Renal anemia | Filed Jul. 09 | Epoetin beta pegol Mircera Injection | Roche Mircera | Continuous erythropoietin receptor activator |
| Transplant, Immunology and Infectious diseases | | | | | |
| RG964 | Compensated liver cirrhosis caused by hepatitis C virus | Phase II / III | ribavirin Copegus Oral | Roche Copegus | Anti-viral agent, in combination with Pegasys |
| RG442 | # Chronic hepatitis B | | Phase II / III | peginterferon alfa-2a Pegasys Injection | Roche Pegasys |
| NA808 | Chronic hepatitis C | Phase I | Injection | In-house | Serine palmitoyltransferase inhibitor |
| | | Phase I Overseas | | | |
| Other diseases | | | | | |
| EPOCH | Predeposit of autologous blood transfusion # | Approved Jun. 10 | epoetin beta Epogin Injection | In-house | Recombinant human erythropoietin |
| CSG452 (RG7201) | Type II diabetes | Phase II Multinational study | tofogliflozin Oral | In-house (Roche) | SGLT2 inhibitor |
| RG1583 (ITM-077) | Type II diabetes | Phase II | taspoglutide Injection | Roche/Ipsen (Teijin) | GLP-1 analogue |

| Development code | Indication # Additional indication | Stage (date) | Generic name Product name Dosage form | Origin Overseas name (Collaborator) | Mode of Action |
|------------------|---------------------------------------|---------------------------------|---|---|---|
| RG1678 | Schizophrenia | Phase II Multinational study | Oral | Roche | GLYT1 inhibitor |
| RG1450 | Alzheimer's disease | Phase I | gantenerumab Injection | Roche/Morphosys | Human anti-amyloid-beta monoclonal antibody |

Changes from the last announcement on July 22, 2010

Oncology

-RG3502 Phase I → Phase II (Breast cancer)
 -AF802 Phase I/II (Non-small cell lung cancer: Starting development)
 -PA799 Phase I (Solid tumor: Starting development/Overseas)

Bone and Joint diseases

-MRA Multinational Phase III → Filed (Systemic onset juvenile idiopathic arthritis (sJIA)/Overseas)
 -RG1594 Multinational Phase III → Development suspended (Rheumatoid arthritis)

R&D Activities (Jul. 1, 2010 – Oct. 22, 2010)

As for clinical development activities in Japan, the Company saw progress as described below:

Oncology

- In October, we started a Phase II trial (expected indication: breast cancer) for a HER2 antibody-drug conjugate, RG3502.
- In September, we started a Phase I/II trial (expected indication: non-small cell lung cancer) for a ALK inhibitor, AF802.

Bone and Joint diseases

- After re-evaluating risk/benefit balance, we have decided to discontinue our development of a Humanized anti-CD20 monoclonal antibody, RG1594 for Rheumatoid arthritis.

At present, we are awaiting the approval of applications (new molecular entities or additions of indications) filed for 7 development themes, including RG435 (expected indication: breast cancer).

Also, as for development activities overseas, the Company saw progress as described below.

- In August, we started a Phase I trial (expected indication: solid tumor) for PA799.
- In October, Roche filed an application for a humanized anti-human IL-6 receptor monoclonal antibody, MRA (product name: Actemra), for Systemic onset juvenile idiopathic arthritis (sJIA).

Major clinical trials in oncology field currently running in Japan

| Theme | Expected Indication | Regimen | Stage | Planned Filing Date |
|--|----------------------------|----------------------------------|---|---------------------|
| RG435 (bevacizumab) Avastin | Breast | paclitaxel + RG435 | Filed (Oct. 09) | - |
| | Breast (adjuvant) | standard chemotherapy ± RG435 | BEATRICE study : Phase III Multinational study | 2013 2015 |
| | Glioblastoma | temozolomide ± RG435 | Phase III Multinational study | 2013 2015 |
| | Glioblastoma [relapsed] | RG435 | Phase II | 2013 2015 |
| RG435 (bevacizumab) Avastin RG340 (capecitabine) Xeloda | Colon (adjuvant) | FOLFOX4 ± RG435 XELOX + RG435 | AVANT study : Phase III Multinational study | 2011 |
| RG1415 (erlotinib) Tarceva | Pancreatic | gemcitabine + RG1415 | Filed (Sep. 09) | - |
| RG597 (trastuzumab) Herceptin RG340 (capecitabine) Xeloda | Gastric | RG340 / 5FU + CDDP ± RG597 | Filed (Mar. 10) | - |
| RG1273 (pertuzumab) | Breast | RG597 + docetaxel ± RG1273 | CLEOPATRA study : Phase III Multinational study | 2013 2015 |